Improving COPD Outcomes: Using Real-World Data to Analyze Treatment Effectiveness, Safety, and Adherence
改善慢性阻塞性肺病的治疗效果:使用真实世界数据分析治疗效果、安全性和依从性
基本信息
- 批准号:10590302
- 负责人:
- 金额:$ 16.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-19 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAddressAdherenceAdrenal Cortex HormonesAgeAgonistAlgorithmsAreaAuthorization documentationAwardAzithromycinBiometryBudesonideCaringCause of DeathCharacteristicsChronicChronic Obstructive Pulmonary DiseaseClinicalClinical TrialsCodeComplexComputerized Medical RecordCosts and BenefitsCoughingDataDatabasesDiseaseDisease OutcomeDoseDrynessDyspneaElderlyEpidemiologyFaceFrequenciesFutureGleanGlycopyrrolateGoalsGrantGuidelinesHealth systemHealthcareHealthcare SystemsHospitalizationInhalationInhalatorsInsuranceInsurance BenefitsInterventionLinkLiteratureLungMachine LearningMentorsMentorshipMorbidity - disease rateMuscarinic AntagonistsOntologyOutcomeOutcome MeasurePatient CarePatientsPerformancePharmaceutic PolicyPharmaceutical PreparationsPharmacoepidemiologyPneumoniaPowder dose formPredictive ValuePublic HealthRandomized, Controlled TrialsResearchResearch PersonnelRiskSafetySample SizeScheduleScientific Advances and AccomplishmentsSeverity of illnessShapesSmoking StatusSpirometrySymptomsTechniquesTestingTrainingTreatment EffectivenessUncertaintyWomanWorkauthorityclinical practiceclinical predictorscomorbiditycomparative effectivenesscomparative effectiveness studycomparative safetycompare effectivenesscostdata managementdesigneducation planningethnic minorityexperiencefluticasoneformoterolimprovedinclusion criteriainsightinsurance claimslongitudinal datasetmachine learning methodmetermortalitynoveloptimal treatmentsracial minorityskillstooltreatment guidelinestreatment strategytrial comparingtrial designvalidation studies
项目摘要
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality worldwide and
is associated with symptoms of dyspnea, cough, and reduced functional capacity. While numerous scientific
advances have been made to improve the care of patients with COPD, considerable uncertainty remains about
optimal management. For some questions, clinical trial data have been conflicting; for others, clinical trials
have not been feasible. Uncertainty in the management of COPD has been further compounded by questions
of generalizability in randomized controlled trials. Studies have demonstrated that the majority of patients with
COPD would not qualify for such trials because of their strict inclusion criteria based on characteristics such as
age, comorbidities, smoking status, and spirometry. Conflicting or absent clinical trial data and questions of
generalizability prompt the need for “real-world” studies of patients treated for COPD in routine clinical practice.
Given poor adherence to inhaler therapy outside of clinical trials, studies are also needed to understand why
patients discontinue therapy. Improving the care of patients with COPD requires identifying which therapies are
most likely to be safe and effective in routine clinical practice and developing interventions to target those least
likely to be adherent. The ultimate goal of the proposed research is to supplement existing data from
randomized controlled trials with pharmacoepidemiologic studies to refine treatment strategies in COPD.
The proposed research will accomplish this goal by using large, longitudinal healthcare databases to
pursue three specific aims: (1) To validate claims-based definitions of COPD exacerbations; (2) To compare
the effectiveness and safety of therapies in the management of COPD, focusing on four areas of ongoing
clinical uncertainty; and (3) To develop a clinical prediction rule of inhaler adherence that incorporates key
variables across several domains, from out-of-pocket costs and insurance benefit design to therapy-related
features (e.g., frequency of dosing) and COPD disease severity. By addressing treatment effectiveness, safety,
and adherence among patients treated in routine clinical practice, the proposed research will glean novel
insights into the management of COPD, particularly for patients who are underrepresented in clinical trials,
including older adults, racial and ethnic minorities, women, and those with complex co-morbidities.
Dr. Feldman has a unique background as a practicing pulmonologist with public health experience. This
K08 proposes an education plan that will help him build new skills in pharmacoepidemiology. He will receive
mentorship from Dr. Sebastian Schneeweiss, a pioneer in pharmacoepidemiology, and Dr. Aaron Kesselheim,
a leading authority on pharmaceutical policy and use, and will rely on a team of scientific advisors with
expertise in machine learning (Dr. Joshua Lin), data management (Dr. Shirley Wang), biostatistics (Dr. Robert
Glynn), geriatric prescribing (Dr. Jerry Avorn), and COPD epidemiology (Dr. Edwin Silverman). This award will
provide Dr. Feldman with the tools needed to become an independent investigator.
慢性阻塞性肺疾病(COPD)是世界范围内主要的死亡原因之一,
与呼吸困难、咳嗽和功能减退的症状有关。虽然无数的科学研究
在改善COPD患者护理方面取得了进展,但仍有相当大的不确定性
优化管理。对于一些问题,临床试验数据是相互矛盾的;对于另一些问题,临床试验
都是不可行的。慢性阻塞性肺疾病管理中的不确定性因问题而进一步加剧
在随机对照试验中的概括性。研究表明,大多数患者患有
COPD没有资格参加这样的试验,因为它们基于以下特征的严格的纳入标准
年龄、合并症、吸烟状况和肺活量测定。冲突或缺失的临床试验数据和问题
概括性促使在常规临床实践中对接受COPD治疗的患者进行“真实世界”研究。
鉴于临床试验以外的吸入器治疗依从性很差,也需要研究来理解为什么
患者停止治疗。改善COPD患者的护理需要确定哪些治疗方法
最有可能在常规临床实践中安全有效,并开发针对那些最不安全的人的干预措施
很可能是追随者。拟议研究的最终目标是补充现有的数据
通过药物流行病学研究改进COPD治疗策略的随机对照试验。
拟议的研究将通过使用大型的纵向医疗数据库来实现这一目标
追求三个具体目标:(1)验证基于索赔的慢性阻塞性肺病加重定义;(2)比较
治疗在COPD管理中的有效性和安全性,重点是正在进行的四个领域
临床不确定性;以及(3)开发吸入器依从性的临床预测规则,其中包括关键
几个领域的变量,从自付成本和保险福利设计到与治疗相关的
特征(例如,给药频率)和COPD疾病严重程度。通过解决治疗的有效性、安全性、
和在常规临床实践中接受治疗的患者的依从性,拟议的研究将收集新的
对慢性阻塞性肺疾病的管理,特别是对在临床试验中代表性不足的患者的见解,
包括老年人、种族和少数民族、妇女和患有复杂并存疾病的人。
作为一名具有公共卫生经验的执业肺科医生,费尔德曼博士有着独特的背景。这
K08提出了一项教育计划,将帮助他在药物流行病学方面建立新的技能。他将收到
来自药物流行病学先驱Sebastian Schneweiss博士和Aaron Kesselheim博士的指导,
是药品政策和使用方面的领先权威,并将依靠一支科学顾问团队,
擅长机器学习(Joshua Lin博士)、数据管理(Shirley Wang博士)、生物统计学(Robert博士
老年处方(曾傑瑞·埃沃恩博士)和慢性阻塞性肺病流行病学(埃德温·西尔弗曼博士)。这一奖项将
为费尔德曼博士提供成为独立调查员所需的工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Brand Feldman其他文献
William Brand Feldman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 16.25万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 16.25万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 16.25万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 16.25万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 16.25万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 16.25万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 16.25万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 16.25万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 16.25万 - 项目类别: